Page 28 - 林口醫研部2021年12月電子報
P. 28
‣研究目的背景
To increasing use of biologics is accompanied by a risk of hepatitis B
(HBV) and C virus (HCV) reactivation.
‣研究發現與應用
To determine the predictors of HBV and HCV reactivation in patients
with psoriasis receiving biologics.
‣研究方法
To determine the predictors of HBV and HCV reactivation in patients
with psoriasis receiving biologics.
‣研究成果
During 8809 and 1522 person-months of follow-up, 88 treatment
episodes for HBV involved HBV reactivation, and 14 episodes of HCV involved
reactivation. The reactivation rate was significantly higher in treatment
episodes of chronic HBV infection than in that of occult HBV (34.3% vs 3.2%,
P = .001) and resolved HBV (34.3% vs 5.0%, P<.001). The multivariate
analysis revealed that being hepatitis B surface antigen seropositive, being
hepatitis B e-antigen seropositive, and tumor necrosis factor- α inhibitor
therapy were risk factors for HBV reactivation, whereas antiviral prophylaxis
was effective in reducing the risk of HBV reactivation. No predictors were
significantly associated with HCV reactivation.
28
